Integration and Challenges of Excipients with Pharmacological Efficacy

Haosheng Zhang

Michigan State University, East Lansing, 48824, USA

Abstract. Excipients are extra compounds that are included with the primary active ingredients in medicinal products. They are essential in enhancing the stability and accessibility of medications. Although excipients are a common component of daily life, incorporating them with pharmaceuticals still offers some difficulties. Although there are many different kinds of excipients, not all of them can completely match a medicine. Excipients will be used in diverse ways as carriers as a result of the various pharmaceutical production methods, which will modify the excipients that are chosen. Excipients often engage in the body's absorption and metabolism just like active pharmaceutical substances do. Different excipients have been tested in vitro and in vivo by researchers. They matched in vitro activity tests of 25 excipients to clinical safety tests. As a result, they discovered an extra 109 activities. Many individuals now understand that considering excipient toxicity is important. Researchers integrated it with cell models in animal trials and discovered that five excipients can predict the fingerprint of systemic toxicity. Additional research is required on the exposure of seven excipients, including thimerosal intestine exposure. Effect and risk ratio are two factors that are taken into consideration while assessing an excipient's safety. When examining a patient's response to a medication and how it varies, drug researchers may come across a range of circumstances. This article's objectives are to introduce the idea of excipients, examine some typical excipient usage instances, and provide an overview of excipient use in pharmaceuticals. Drug development is a dynamic process that is always changing. Although excipients have been employed in therapeutic settings, there are still a great deal of undiscovered excipients that require further study, analysis, and summarization.

Keywords: excipients; vitro; exposure; toxicity; pharmaceutical.

1. Introduction

Internationally, excipients are considered as inactive ingredients and they undergo a stringent safety assessment process in order to effectively aid in the delivery of drugs. Excipients and drug application are related in a number of ways. They are the main ingredients in the majority of pharmaceutical preparations, and they can improve a drug's taste and flavor, increase its stability and effectiveness, reduce side effects, and even enhance its aesthetics.

Clinical application reflects the significance of excipients. Experts in traditional Chinese medicine consider the processing of mineral excipients2. The primary components of traditional Chinese medicine are derived from plants and animals, which means that they have higher levels of toxicity and impurities. The stages of decocting, forging, steaming, and boiling can effectively reduce toxic and adverse effects when adding auxiliary ingredients. They come in a wide range of varieties. Excipients are commonly applied in various contexts besides therapeutic settings. Due to their exceptional viscosity, pectin and lactose, for example, are used in the manufacturing of pharmaceuticals. Propyl gallate (PG), an antioxidant, can prolong the shelf life of food additives.

Excipients, however, also have some detrimental effects on the medicine. After taking medications that contain excipients, some patients experience allergic responses, such as skin redness or vomiting. Even if the excipient and the drug's names are completely different, They have many similarities in structure (Figure 1). As a result, excipients are chosen and used based on a number of variables, including the nature of the medicine, production needs, and therapeutic goals.



Figure 1. The structures of Benzocaine and Ethylparaben are comparable. However, one serves as a drug and the other as an excipient.1

By collecting the current literature, this study primarily expresses and examines the use of various excipients in medicine. Consider how structure, content, and reaction mechanism affect how excipients and medications interact.

2. Excipient can affects the utilization efficiency of drug

Initially, it was believed that because the majority of excipients were biologically inert, they did not trigger physiologically active reactions in living things. Excipients operate as carriers for active pharmaceutical ingredients (APIS) to comply with the consistent requirements in the formulation. The pressure patients experience during treatment is lessened by the varied applications of pharmacological excipients. However this isn't always the case. Excipients are no longer regarded as inert compounds since, according to Cátia G. Abrantes, Dinah Duarte, and Catarina P. Reis (2016), they might interact with the API and lessen its potency.

It was demonstrated in one investigation that some excipients can connect to biological targets and have pharmacological effects under specific circumstances. An example is that bicarbonate-containing drugs (Paracetamol)3 improve the pace of stomach emptying and absorption of acetaminophen. The investigator conducted tests on 12 healthy subjects in the state of fasting and eating. Concentrations in the medication were then examined by scanning and measuring blood serum in the subjects. During the practice, volunteers will be placed into 4 different groups (A, B, C, and D). Volunteers in groups A and C need to be maintained on an empty stomach, while volunteers in groups B and D need to eat before starting the experiment. Participants in Group A then took 2 pills that did not include bicarbonate (P). In order to compare with the experiment in group A, the participants in group C were obliged to take 2 tablets containing bicarbonate (PA). Likewise, participants in group B received the medicine without bicarbonate (P), whereas those in group D received the drug with bicarbonate (PA). According to the results given in Table 1, the average dissolving time of the drug containing bicarbonate is faster than that of the general drug and the difference in stomach emptying is more noticeable in the fasting state.

Table 1. The time of PA under fasting is 10.2 minutes, while the time of P is 22.5 minutes. PA is 14.3 minutes with fed and P is 46.4 minutes3.

	PA fasted	PA fed	P fasted	P fed
Dis. time (min)	10.2 (9.3)	14.3 (11.0)	22.5 (12.8)	46.4 (38.0)
Onset (min)	8.2 (15.7)	15.2 (11.5)	23.4 (22.2)	50.2 (48.6)
t_{50} (min)	22.4 (33.5)	76.9 (30.5)	47.5 (33.5)	106.4 (52.5)
t_{90} (min)	30.9 (35.6)	152.7 (39.4)	64.1 (37.6)	155.5 (55.1)

Another illustration is an experiment where PEG 400 was used to accelerate the small intestine's motion4. Six healthy men were instructed to simultaneously consume 150ml of water with 150mg of ranitidine each by the researchers. They need to repeat the same procedure 4 times. The only variation is that the four cups of water each contain 0, 1, 2.5, or 5g of PEG 400, respectively. To determine how much ranitidine was absorbed, the research team would take 24-hour urine samples. Table 2 lists

the durations of the four tests as 298, 270, 239, and 230 minutes. This shows that higher PEG 400 concentrations cause the solution's transit time through the small intestine to be shortened. This might be because the majority of PEG is expelled with feces as it cannot be absorbed by the digestive system. Ranitidine's bioavailability was lowered by 38% by 2.5g and 5G PEG 400 when it came to absorption, but it rose by 41% when 1g PEG 400 was used (Table 3). Reduced intestinal transit time may thus adversely affect the absorption of ranitidine at higher PEG 400 doses.

Table 2. Different Concentration of PEG 400 on Small Intestinal Transit4

	Mean small intestinal transit time (MSITT) (min)			
Volunteer	Control	1 g PEG 400	2.5 g PEG 400	5 g PEG 400
1	291	225	242	249
2	242	270	199	218
3	283	295	232	188
4	199	271	205	144
5	288	202	227	269
6	486	357	330	309
Mean	298	270	239	230
SD	99	54	47	59
P value		0.412	0.042	0.037

Table 3. Different Concentration of PEG 400 on Ranitidine Absorption4

	Cumulative amount of ranitidine excreted in 24 hours (mg)			
Volunteer	Control	1 g PEG 400	2.5 g PEG 400	5 g PEG 400
1	29	46	29	27
2	31	46	19	25
3	25	40	14	17
4	41	52	23	23
5	15	35	20	16
6	62	68	18	18
Mean	34	48	21	21
SD	16	11	5	5
P value		0.001	0.116	0.117

Pharmaceuticals typically match their active ingredients with molecular targets, which are particular biomolecules and have particular biological effects. In the technique, Researchers frequently employ strategies like biological tests and computer simulations to evaluate and control the impact of excipients on molecular targets. In order to ascertain whether the excipient can provide the desired results, in vitro testing of target excipient activity often entails evaluating the specificity and intensity of binding to the target molecule in a laboratory setting. To make sure they don't affect the environment or people's health, some toxic compounds need additional research and testing. To find workable targets, the researchers first ran calculations on 3,000 proteins1. Second, they examined a panel of 28 toxicity-related targets1, as well as numerous other significant drug toxicity targets. Finally, the researchers examined 73 commonly used excipients 1.5 and Cav 1.21.

3. Researchers can use CSEA and QSPR models to screen medicines

The chemical and computer sciences are closely related in the Cheminformatics Similarity Ensemble Approach (CSEA). Based on the similarity between ligands and proteins, it is used to solve a variety of chemistry-related issues, including database exploration, chemical information retrieval, and chemical information extraction.

To aid computer-assisted drug manufacturing, the researchers will also use a variety of techniques, including machine learning. Computer scientists create machine learning algorithms, which are seamlessly incorporated into chemical models. Machine learning techniques are more practical for researchers than other models because they enable the collection of big data sets without the need for a large amount of computing infrastructure. Researchers can simultaneously thoroughly comprehend and put to use the relationship between chemical structure and its biological function. In the past, it took a lot of time and drug cycle analysis to find a solution if we wanted to increase the affinity binding between the drug and the hit chemical. However, machine learning techniques are currently being used in artificial intelligence programs to model quantitative structure-property relationships (QSPR) and more precisely forecast the impacts of chemical alterations on biological behaviors, such as drug toxicity or carcinogenicity.

As part of the computational process in cheminformatics, molecular properties need to first be retrieved. Apply chemical descriptors and lock compounds from databases to understand the chemical structure of molecules. Chemical descriptors can be used to examine and forecast the variety of compounds. Then, experimenters use chemical fingerprints based on the similarities and differences in molecular features. Chemical fingerprinting, which compares molecules based on similarities, is often used in analytical metrology and screening. Finally, the QSAR/QSPR model enables the computer to train and learn based on the pharmacophore and chemical properties of the drug (Figure 2).



Figure 2. Machine Learning in Chemoinformatic: A Step-by-Step Guide5

One of the basic methods used frequently in QSPR modeling is chemical similarity. It makes the supposition that if two chemicals have comparable structures, they are probably going to have comparable biological activities. However, this presumption is debatable because there are various techniques to determine chemical similarity. For instance, comparing common molecules between two ligands computationally using 3D structural characteristics. Pharmacophore similarity, which is

one of the 3D structural properties, need to take into account the substantial overlap between important functional groups.

CSEA, which is based on the idea of chemical similarity, is used to identify the new drug candidates and discover the new drugs. Researchers evaluate and contrast the similarities and differences between two molecules' molecular properties and structure. They can then uncover compounds that are likely to be active against particular targets and anticipate the activity of novel compounds using a variety of machine learning algorithms. Then, using ensemble approaches, a large number of new compounds are integrated to give predictions that are more accurate and dependable. The active target molecules were eliminated after a large number of compounds were screened. A computer screen of 3117 human targets (from the ChEMBL database) yielded more than 20,000 options for the researchers. They also sequenced 69 excipients utilizing visual analysis of excipients and target ligands, with a success rate of 36%, and discovered a total of 25 excipients with target activity1.

4. BioMAP can simulate medications in human disease models

The majority of excipients cannot demonstrate their functional activity and toxicity during the determination procedure, despite the fact that CSEA can aid experimenters in drug screening. Therefore, to evaluate cytotoxicity, researchers use excipient-based cellular tests. The researchers decided to employ the BioMAP Diversity PLUS panel to conduct extra testing on 12 active excipients of interest in an effort to overcome the influence of harmful side effects on human health in the process of predicting pharmaceuticals (Figure 3). With its human cell foundation, BioMAP can meet the demands of in vitro models of comparable diseases. This method of simulating biological processes is frequently employed to chemically encourage the growth of different cell types (such as immune cells, vascular endothelial cells, intestinal cells, etc.) in living things in order to replicate the effects of medications. Researchers can evaluate drug side effects and even cell type interactions using this technique to better understand how drugs interact with organisms and create novel medications.

The collection of multiparametric data produced by a specific BioMAP system to aid reagents serves as the BioMAP acceptance criterion in the statistical and analytical process. These include negative controls, controls on drugs, and controls on vehicles. The BioMAP assay is plate-based, therefore both the plate's performance and the system's performance can affect the requirements for getting results. Through a choice of 148 biomarker readings6, BioMAP Diversity PLUS may assess the therapeutic and biological relevance of a sample. These data can correctly and clearly show the course of an illness or the effects of medications. Once validated, researchers can use widely known medications. There are four biomarkers (Ruxolitinib, Fedratinib, Momelotinib, and Pacritinib) in panels A through D of figure 3. Each drug's unique mechanism is mirrored by a different set of biomarkers. At 700 nM, Momelotinib decreased PBMC viability, but not to the level that had been set. Fedratinib (1.1 μM) has no impact on the viability of PBMCs.



Figure 3. X-axes show the readout of a constant protein concentration in the biomarker and the system endpoint for proliferative activity. Y-axes show the number of log-transformed biomarker readings (test agent/vehicle control)6.

Table 4. Summary of Four Biomarkers' Antiproliferative and Activity6

Test Agents	Concentrations	Detectable Cytotoxicity[a]	Antiproliferative Effects[b]	Inflammation-Related Activities[c]	Immunomodulatory Activities[c]	Tissue Remodeling Activities[c]	Hemostasis-Related Activities[c]
Ruxolitinib	700, 230, 78,26	None	B cells (700, 230), T cells (700, 230, 26)	↓ Eotaxin 3, E-selectin, VCAM-1, MCP-1, sTNFα, I-TAC, ICAM-1, MIG, IP-10, IL-1α, P-selectin ⇵ IL-8	↓sIgG, M-CSF, HLA-DR, CD38, sIL-6, sIL-17F ↑sIL-2 ⇵CD69	↓uPAR ↑ PAI-1, MMP-9	↓TF
Fedratinib	1100, 370, 120, 41	None	B cells (1100) T cells (1100) Endothelial cells (1100)	↓Eotaxin 3, VCAM-1, I-TAC, MIG	↓sIgG, sIL-6 ↑ sIL-2	↑PAI-1	None
Momelotinib	700, 230, 78, 26	None	B cells (700, 230) T cells (700) CASM cells (700)	↓Eotaxin 3, E-selectin, VCAM-1, sTNFα, I-TAC, MIG, IL-8, $sPGE_2$	↓CD40, sIL-10, sIL-17A, sIL-6, CD69	None	↓TF
Pacritinib	700, 330, 230, 110, 78, 37, 26	PBMC (SAg and BT; 700)	B cells (330, 230 110, 78)	↓ sTNFα	↓sIgG, sIL-17A, sIL-6, sIL-17F, sIL-2 ↑CD69	↓ MMP9	None

[a] (system; concentration)
[b] (concentration)
[c] ↑ Indicates an increase relative to vehicle control; ↓indicates a decrease relative to vehicle control; ⇵ indicates an increase in some but not in others relative to vehicle control.

A pool of donors of various human primary cells makes up the BioMAP system. Key elements of disease can be summed up by using them to preserve and store physiological regulatory networks. Researchers evaluated more than 4,000 pharmacological and chemical references in the BioMAP database. A good example is the excipient propyl gallate, which is utilized in the co-formulation of

medications including Simvastatin, Janumet, Ezetimibe, and Advil Sinus Congestion and Pain. Propyl gallate inhibits the proliferation of B and T cells at certain doses (10 to 30 M). Cellular activity of immunosuppressive medications may influence their immunomodulatory and inflammatory effects. Additionally, at lower concentrations, the inhibitor propyl gallate, which has anti-inflammatory and immunomodulatory properties, appeared to have effects comparable to those of phenethyl caffeate.

5. Drug transporters determine the pharmacokinetics of statin toxicity in humans

The utilization of the transporters bile salt export pump (BSEP) and OATP2B1 is really important in pharmacokinetics. A crucial protein that can take part in the transport of bile acids is the BSEP. It moves bile acids from the liver to the bile ducts, modifying how well medicines are excreted through the bile and changing their pharmacokinetic characteristics and effectiveness. The acid balance of hepatic bile can be regulated and maintained with the use of BSEP. Lack of BSEP in the enterohepatic cycle impairs bile flow and may cause cholestatic liver disease. On the other hand, the expression of organic anion transporting polypeptide (OATP2B1) is diverse in organs and cells (Figure 4). The OATP2B1 allows excipients to enter cells where they are transformed into active medications. OATP2B1 may, however, have an impact on the hepatic absorption and elimination of medications, participate in their pharmacokinetics, and alter both their pharmacokinetic properties and efficacy. Jonny Kinzi, Markus Grube, and Henriette E. Meyer zu Schwabedissen (2021) claim that research on food-drug interactions is where most observations concerning OATP2B1 come from. OATP2B1 polymorphism affects the bioavailability of many medicines in a variety of ways. But many studies on OATP2B1 have not produced reliable results due to the limits of data collection.



Figure 4. Overview of tissues exhibiting apical OATP2B1 expression8

Pravastatin is frequently used as a substrate by many drug transporters. It and several other statins are actively transferred from the portal vein to stem cells by taking up transporters. Pravastatin is more quickly absorbed when intestinal epithelial cells express OATP2B1. Pravastatin's bile content can be reduced by stem cells expressing BSEP.

The researchers conducted a counter-screen utilizing active excipients for colloidal aggregation and observed aggregated excipients, which might be considered human elements. Along with other targets including VMAT2 and Nav, 28 clinically relevant targets for safety were examined. Finally, 73 frequently utilized excipients were gathered by the researchers1. 32 excipients were found to be active against one or more targets based on the findings1. The medicines were shown to be active between 15 nM to 260 μM by both methods, and their median affinity was around 20 nM.

6. Animal models can be used for systemic exposure and safety assessment of excipients

Before excipients to circulate in the body, they typically need to pass through metabolic and intestinal barriers. Researchers will utilize 7 various but typical excipients to combine with rodent models and observe exposure. Animal models can be used to assess the safety and possible toxicity of excipients. The use of multiple animals for testing enables a more thorough assessment of systemic excipient exposure. After putting the drug to the animals orally, the researchers examined their body fluids (blood or urine). The findings demonstrated that most medicines had very low blood levels (Table 5), particularly at their peak concentrations. The highest value of FD&C Red No.3 is 17nM, which is not concerning when compared to the value of 92nM. It also implies that the excipient will either be sequestered in the stomach or quickly digested regardless of how active its target or cellular systems are.

Table 5. With the above excipients administered intravenously and orally, rat pharmacokinetic characteristics were examined1

Excipient	Target	IC_{50} (μM)	MDCK-LE P_{app} ($\times 10^{-6}$ cm/s)	$t_{1/2}$ from i.v. dose (hours)	i.v. AUC (nM·hour) 0–24 (d.n.)	Oral AUC (nM·hour) 0–last (d.n.)	Oral C_{max} (nM)	%F
Butylparaben	TBXA2R	19	8.3	N.D.*	N.D.*	N.D.*	<2.6	N.D.*
Cetylpyridinium chloride	DRD3	0.55	<0.5	9.7	15,972	4,052	260	5.4
FD&C Red No. 3	PDE3A	0.092	<0.5	3.4	4,826	32	16.9	0.7
D&C Red No. 6	SLCO1B1	3.1	<1.2	6.9	30,511	776	164	2.5
Diethyl phthalate	PDE4D2	16	–	1.0†	553†	350†	253†	N.D.†
Propyl gallate	COMT	0.015	11.7	4.9	6908	N.D.*	<8.9	N.D.*
Thimerosal	DRD3	0.32	–	24.2‡	N.D.	N.D.	30 to 40 ng/g‡ (70 to 105 nM)	N.D.

Evidence suggests that COMT may potentially affect intestinal problems. It is broken down by COMT, an enzyme that controls the stomach's metabolism of catecholamine neurotransmitters including dopamine and adrenaline. Excipients are often incorporated into medicine formulations as inert components; therefore they rarely have direct interactions with COMT or other particular enzymes. Some indirect interactions are possible, though. Levodopa is an special case. Parkinson's disease is frequently treated with medications that include levodopa. But when levodopa and COMT are coupled, this enzyme may have an impact on other processes including medication absorption, distribution, or metabolism. The role of COMT in the digestive system demonstrates the intricate interactions between the stomach and the central nervous system. Additionally, the central nervous system is where the majority of COMT's functions are primarily expressed, and therapeutic exposure to the brain is significantly smaller than that to systemic circulation.

7. Conclusion

Overall, excipients are essential to the preparation and administration of medicines. Despite being commonly thought of as having only minimal biological activity, inactive compounds utilized in medications may nonetheless be able to interact with biological targets in the body. Numerous inactive components of medicines can in vitro have direct physiologically meaningful effects on enzymes, receptors, and ion channels. These inactive components may have an impact on a patient's ability to absorb the medication.

The stability of the API can be controlled and maintained by the use of several excipients, which are employed in much higher concentrations than the API. The majority of pharmaceutical excipients restrict the maximum dose. However, if a medicine is used consistently over a lengthy period of time, it also suggests that the excipient is consistently used. This could lead to excipient dosages exceeding the maximum recommended dose and raising systemic levels. The safety and efficacy of the substance itself should be taken into account while choosing excipients. To lessen its effect on people's health, experts will carry out further research and experimental tests.

Acknowledgements

I want to convey my gratitude to the research team and colleagues that helped me finish my academic work and explore this subject. They have gathered and distilled invaluable experience that will be helpful to us as we continue to explore and examine the world of biological targets. I also like to thank all the volunteers who took part in the tests as they were essential to the study. In addition, I want to thank Professor Ruben Savizky from the bottom of my heart. I now have a deeper understanding of excipients and biological targets thanks to his direction and explanations in class. He was a huge assistance to me as I was studying. Last but not least, I want to thank my friends and family for helping me with this study and for their many helpful recommendations.

References

[1] The Activities of Drug Inactive Ingredients on Biological Targets | Science, www.science.org/doi/10.1126/science.aaz9906. Accessed 14 July 2023.

[2] Liu, Yan, et al. “Effect of Mineral Excipients on Processing Traditional Chinese Medicines: An Insight into the Components, Pharmacodynamics and Mechanism - Chinese Medicine.” BioMed Central, 6 Jan. 2022, cmjournal.biomedcentral.com/articles/10.1186/s13020-021-00554-8.

[3] Kelly, Kilian, et al. “Comparison of the Rates of Disintegration, Gastric Emptying, and Drug Absorption Following Administration of a New and a Conventional Paracetamol Formulation, Using γ Scintigraphy-Pharmaceutical Research.” SpringerLink, link.springer.com/article/10.1023/A:1026155822121. Accessed 14 July 2023.

[4] Schulze, Julia D. R., et al. “Concentration-Dependent Effects of Polyethylene Glycol 400 on Gastrointestinal Transit and Drug Absorption - Pharmaceutical Research.” SpringerLink, link.springer.com/article/10.1023/B:PHAM.0000008046.64409.bd. Accessed 14 July 2023.

[5] RB;, Lo YC;Rensi SE;Torng W;Altman. “Machine Learning in Chemoinformatics and Drug Discovery.” Drug Discovery Today, pubmed.ncbi.nlm.nih.gov/29750902/. Accessed 15 July 2023.

[6] Singer, Jack W., et al. “Comparative Phenotypic Profiling of the JAK2 Inhibitors Ruxolitinib, Fedratinib, Momelotinib, and Pacritinib Reveals Distinct Mechanistic Signatures.” PLOS ONE, journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0222944. Accessed 15 July 2023.

[7] Author links open overlay panelCátia G. Abrantes 1, et al. “An Overview of Pharmaceutical Excipients: Safe or Not Safe?” Journal of Pharmaceutical Sciences, 1 June 2016, www.sciencedirect.com/science/article/abs/pii/S0022354916004470.

[8] Author links open overlay panelJonny Kinzi a, et al. “OATP2B1 – the Underrated Member of the Organic Anion Transporting Polypeptide Family of Drug Transporters?” Biochemical Pharmacology, 29 Mar. 2021, www.sciencedirect.com/science/article/pii/S0006295221001301.

[9] Kivistö, Kari T., and Mikko Niemi. “Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans - Pharmaceutical Research.” SpringerLink, 20 Dec. 2006, link.springer.com/article/10.1007/s11095-006-9159-2.